nonacog beta pegol

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

2 competitors in Congenital Bleeding Disorder

Drug Information

Target Indication

Congenital Bleeding Disorder

Clinical Trial

Last updated: 12/10/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Regulatory Approvals

EMA6/2/2017

Refixia

Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency). Refixia can be used for all age groups.

Drug Science

Mechanism of action & safety profile

Developer

NVO

Novo Nordisk A/S

Related Pipeline

Obesity or Overweight

Transthyretin Amyloid Cardiomyopathy (ATTR CM)

Diabetes

Obesity

Congenital Bleeding Disorder

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts